| 2018-05 |
A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Meeting Abstract e16204. |
|
| 2018-04 |
The role of consolidation chemoradiotherapy in Locally Advanced Pancreatic Cancer receiving chemotherapy: An updated systematic review and meta-analysis |
Cancer Research and Treatment. 2018 Apr;50(2):562-574. |
 |
| 2018-04 |
Dialysis increases the risk of bladder recurrence in patients with Upper Tract Urothelial Cancer: A population-based study |
Annals of Surgical Oncology. 2018 Apr;25(4):1086-1093. |
|
| 2018-03 |
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use |
Kaohsiung Journal of Medical Sciences. 2018 Mar;34(3):181-183. |
|
| 2018-03 |
Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy |
Journal of Cancer Research and Practice. 2018 Mar;5(1):27-31. |
|
| 2018-02-01 |
Myeloid-derived macrophages and secreted HSP90alpha induce pancreatic ductal adenocarcinoma development |
OncoImmunology. 2018 Feb 1;7(5):Article number e1424612. |
|
| 2018-02 |
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 460. |
|
| 2018-02 |
Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1. |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 459. |
|
| 2018-02 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 90. |
|
| 2018-02 |
Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):388. |
|
| 2018-02 |
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) p |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):379. |
|
| 2018-02 |
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):410. |
|
| 2018-01 |
Orchestration of H3K27 methylation: Mechanisms and therapeutic implication |
Cellular and Molecular Life Sciences. 2018 Jan;75(2):209-223. |
|
| 2018-01 |
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS |
Annals of Oncology. 2018 Jan;29(1):44-70. |
|
| 2018-01 |
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma |
Journal of Clinical Oncology. 2018 Jan;36(3):276-282. |
|
| 2018-01 |
Environmental tobacco smoke and risk of pancreatic cancer among never smokers |
Cancer Science. 2018 Jan;109(Suppl. 1):769. |
|
| 2018-01 |
Role of academic institute in cancer therapy development in National Institute of Cancer Research, NHRI in Taiwan |
Cancer Science. 2018 Jan;109(Suppl. 1):43. |
|
| 2018-01 |
The role of aberrant mitochondrial phosphoenolpyruvate carboxykinase expression in pancreatic neuroendocrine tumors |
Cancer Science. 2018 Jan;109(Suppl. 1):466. |
|
| 2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial |
Lancet. 2017 Dec;390(10111):2461-2471. |
|
| 2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy |
Annals of Oncology. 2017 Nov;28(Suppl. 10):67-U261. |
|
| 2017-11 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) � 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2017 Nov;28(Suppl. 10):Meeting Abstract 227P. |
|
| 2017-10-24 |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan |
Journal of the Formosan Medical Association. 2018 May;117(5):381-403. |
|
| 2017-10-09 |
Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors |
Oncotarget. 2017 Oct 09;8(61):103613-103625. |
|
| 2017-10 |
Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review |
Cancer Research and Treatment. 2017 Oct;49(4):851-868. |
|
| 2017-10 |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma |
Scientific Reports. 2017 Oct;7:Article number 14333. |
|
| 2017-09-16 |
The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors |
Oncotarget. 2017 Sep 16;8(58):98068-98083. |
|
| 2017-09 |
KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the KrasG12D p53flox/flox model |
Oncogene. 2017 Sep;36(39):5532-5543. |
|
| 2017-09 |
A phase II study of Arginine Deiminase (ADI-PEG20) in relapsed/refractory or poor-risk acute myeloid leukemia patients |
Scientific Reports. 2017 Sep;7:Article number 11253. |
|
| 2017-09 |
ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 777TiP. |
|
| 2017-09 |
ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 778TiP. |
|
| 2017-09 |
Inhibition of the ubiquitin-conjugating enzyme E2B restores the BCNU sensitivity of cancer cells by regulating MGMT ubiquitination |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 55P. |
|
| 2017-09 |
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 741P. |
|
| 2017-09 |
Mutant KIT translocates into the nucleus and induces NFKBIB expression that leads to KIT expression in imatinib-resistant gastrointestinal stromal tumors |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 1679P. |
|
| 2017-09 |
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37) |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 671P. |
|
| 2017-09 |
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02) |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 617O. |
|
| 2017-08 |
Overexpressed fatty acid synthase in gastrointestinal stromal tumors: Targeting a progression-associated metabolic driver enhances the antitumor effect of imatinib |
Clinical Cancer Research. 2017 Aug;23(16):4908-4918. |
|
| 2017-08 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo |
Cancer Chemotherapy and Pharmacology. 2017 Aug;80(2):307-315. |
|
| 2017-07 |
A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17 |
Oncotarget. 2017 Jul;8(27):44121-44130. |
|
| 2017-06-26 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy |
Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD - 018. |
|
| 2017-06-26 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD-017. |
|
| 2017-05-04 |
Chemotherapy in the management of pancreatic cancer |
Pancreatic Cancer: With Special Focus on Topical Issues and Surgical Techniques. 2017 May 4:387-419. |
|
| 2017-05 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: A Q-TWiST analysis |
British Journal of Cancer. 2017 May;116(10):1247-1253. |
|
| 2017-05 |
The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM |
Journal of Clinical Oncology. 2017 May;35:Meeting Abstract e15795. |
|
| 2017-05 |
A phase I dose escalation study of SCBO1A, a micro tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy |
Journal of Clinical Oncology. 2017 May;35(Suppl. 15):Meeting Abstract 2531. |
|
| 2017-02 |
Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: Applicability to clinical situations |
Journal of Clinical Oncology. 2017 Feb;35(6):689-690. |
|
| 2017-02 |
The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21) |
Journal of Pathology. 2017 Feb;241(3):420-433. |
|
| 2017-02 |
Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells |
Oncology Reports. 2017 Feb;37(2):969-978. |
|
| 2017-02 |
A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer |
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):417. |
|
| 2017-02 |
Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO |
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):303. |
|
| 2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial |
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):2. |
|
